While still downplaying the potential risk to humans as testing continues after avian influenza was detected in 20% of milk sampled, administration officials Thursday (April 25) said FDA is working with industry on an appropriate regulatory pathway for rolling out vaccines made with that bulk antigen if necessary, and a vaccination prioritization plan based on responses to previous disease outbreaks is available if needed. Yet officials did not sound an alarm, while acknowledging there is a lot of scientific uncertainty...